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BSTRACT
 
Background
 
Infection with human herpesvirus 8
(HHV-8) has been consistently linked to Kaposi’s sar-
coma, but its mode of transmission, association with
other cancers, and interaction with the human im-
munodeficiency virus type 1 (HIV-1) are largely un-
known.
 
Methods
 
Between January 1992 and December
1997, we interviewed 3591 black patients with cancer
in Johannesburg and Soweto, South Africa. Blood
was tested for antibodies against HIV-1 and HHV-8 in
3344 of the patients. Antibodies against HHV-8 were
detected with an indirect immunofluorescence as-
say. The intensity of the fluorescent signal correlated
well with the titers of antibodies (P<0.001). The rela-
tions among the presence of anti–HHV-8 antibodies,
sociodemographic and behavioral factors, type of
cancer, and the presence or absence of coexistent
HIV-1 infection were examined with the use of un-
conditional logistic-regression models.
 
Results
 
Among the 3293 subjects with cancers
other than Kaposi’s sarcoma, the standardized sero-
prevalence of antibodies against HHV-8 was 32 per-
cent, which did not differ significantly from the
standardized seroprevalence among black blood do-
nors. Among these 3293 patients, the prevalence of
antibodies against HHV-8 increased with increasing
age (P<0.001) and an increasing number of sexual
partners (P=0.05) and decreased with increasing
years of education (P=0.007); it was not strongly as-
sociated with HIV-1 infection. Anti–HHV-8 antibodies
were more frequent among black than white blood
donors (P<0.001). Among the 51 patients with Kapo-
si’s sarcoma, the standardized seroprevalence of an-
tibodies against HHV-8 was 83 percent, significantly
higher than the prevalence among those without Ka-
posi’s sarcoma (P<0.001). For 16 other specific types
of cancer, including multiple myeloma (108 cases)
and prostate cancer (202 cases), the variation in the
standardized seroprevalence of antibodies against
HHV-8 was not remarkable. At a given intensity of
fluorescence of anti–HHV-8 antibodies, Kaposi’s sar-
coma was more frequent among HIV-1–positive pa-
tients than among those who were HIV-1–negative
(P<0.001).
 
Conclusions
 
Among black patients with cancer in
South Africa, the seroprevalence of anti–HHV-8 anti-
bodies is high and is specifically associated with Ka-
posi’s sarcoma, particularly at high titers. (N Engl J
Med 1999;340:1863-71.)
 
©1999, Massachusetts Medical Society.
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UMAN herpesvirus 8 (HHV-8, also
known as Kaposi’s sarcoma–associated
herpesvirus) has been consistently linked
to Kaposi’s sarcoma.
 
1-3
 
 HHV-8 is detect-
able in the lesions of nearly all patients with Kaposi’s
sarcoma,
 
4,5
 
 and its presence in the blood predicts the
development of Kaposi’s sarcoma.
 
6,7
 
 This neoplasm
occurs frequently in patients with the acquired immu-
nodeficiency syndrome (AIDS),
 
8
 
 but it was common
in central Africa even before the advent of AIDS.
 
9
 
With the AIDS epidemic now spreading through cen-
tral and southern Africa, Kaposi’s sarcoma has become
the most commonly diagnosed cancer in some coun-
tries in those regions.
 
10,11
 
 The incidence of Kaposi’s
sarcoma is increasing rapidly in South Africa.
 
12
 
 In the
United States and most of Europe Kaposi’s sarcoma,
which was rare before the advent of AIDS, now oc-
curs mainly among homosexual men with AIDS.
 
8
 
Little is known about the transmission of HHV-8,
its association with other cancers, or its interaction
with the human immunodeficiency virus type 1
(HIV-1). The few studies investigating the spread of
HHV-8 infection have tended to be small, but they
suggest that the routes include sexual transmission
among homosexual men in the United States
 
13
 
 and
mother-to-child transmission in South Africa.
 
14
 
HHV-8 has also been found in association with
primary-effusion lymphoma in patients with AIDS,
 
15-17
 
and some investigators have suggested, largely on the
basis of molecular studies, that multiple myeloma
 
18
 
and prostate cancer
 
5
 
 are also associated with HHV-8
infection. These reports, however, have not been con-
firmed.
 
19-22
 
 We studied the relations among the pres-
ence of antibodies against HHV-8, the risk of cancer,
and other factors, including the presence or absence
H
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of HIV-1 infection, in over 3000 black patients from
Johannesburg and Soweto, South Africa, in whom
cancer was diagnosed between 1992 and 1997.
 
METHODS
 
Study Population
 
Data from two large epidemiologic studies conducted by re-
searchers from the South African National Cancer Registry and
the Department of Medicine of the University of the Witwa-
tersrand, in collaboration with investigators in the United King-
dom, are included in this report. In the first study, performed be-
tween January 1992 and December 1994, information was
collected on the age, sex, and birthplace of 1015 black inpatients
with cancer at the Chris Hani–Baragwanath, Hillbrow, and Jo-
hannesburg hospitals, which are the main teaching hospitals in
Johannesburg and Soweto.
 
12
 
 In the second study, performed be-
tween January 1994 and October 1997, trained nurses inter-
viewed 2576 black inpatients with cancer at the same three hos-
pitals using a standard questionnaire in the language of the
patient (usually Zulu or Sotho). Questions were asked about so-
ciodemographic and behavioral characteristics, including age, sex,
birthplace, residence, years of education, and reproductive and
lifetime sexual history. Diagnoses of cancer were established,
where appropriate, by biopsy, examination of blood or bone mar-
row, or cytologic techniques, or by a combination of these meth-
ods. Both studies were approved by the ethics committee of the
University of the Witwatersrand, and informed consent was ob-
tained. For comparative purposes, serum samples were obtained
consecutively from 85 black and 224 white blood donors at the
Johannesburg blood-transfusion service (unpublished data). Sam-
ples were collected in each study and stored at ¡30°C.
 
Serologic Tests for HHV-8 and HIV-1
 
The serum samples were shipped by air on dry ice to the Insti-
tute of Cancer Research in London for HHV-8 testing. All assays
were performed by a single observer who was unaware of each
patient’s personal characteristics and diagnosis. A body-cavity–
related B-cell lymphoma (primary effusion lymphoma) cell line,
BCP-1, which is positive for HHV-8 and negative for the Ep-
stein–Barr virus (EBV), was used for an indirect immunofluores-
cence assay to detect IgG antibodies against HHV-8 antigen.
 
23,24
 
Latently infected BCP-1 cells were fixed in 4 percent paraformal-
dehyde and were made permeable with 0.2 percent Triton X-100.
Cells were resuspended in phosphate-buffered saline and fixed on
glass slides. The samples were diluted 1:100 in phosphate-buffered
saline with 3 percent fetal-calf serum. The diluted serum was add-
ed to the fixed BCP-1 cells and incubated at 22°C for 45 minutes.
After the slides were washed in phosphate-buffered saline with
3 percent fetal-calf serum, rabbit antihuman IgG labeled with
fluorescein isothiocyanate (Dako, High Wycombe, United King-
dom), diluted 1:40 in phosphate-buffered saline with 3 percent
fetal-calf serum, was added, and the slides were incubated at 22°C
for 20 minutes. The slides were then washed in phosphate-buff-
ered saline without fetal-calf serum and screened by ultraviolet
microscopy for the nuclear stippling pattern characteristic of an-
tibodies against the latent nuclear antigen of HHV-8 encoded by
orf 73.
 
23,25-29
 
 The HHV-8–negative cell lines Raji and Daudi were
used as controls.
Serum samples that were positive for antibodies against
HHV-8 by the immunofluorescence assay were then scored as
low, medium, or high according to the intensity of the fluores-
cent signal. These scores correlated well with the intensity of flu-
orescence as measured by fluorescence-activated cell-sorter (FACS)
analysis. Fig. 1A shows the results of FACS analysis for six sub-
jects, two of whose samples had been scored as low, two as me-
dium, and two as high in terms of the fluorescent-signal intensi-
ty. The reproducibility of these results was examined whenever
there was sufficient serum for retesting from the patients with
Kaposi’s sarcoma (47 patients) and from 94 matched controls
without Kaposi’s sarcoma (for each retested sample from a pa-
tient with Kaposi’s sarcoma, we selected serum samples from
2 control subjects without Kaposi’s sarcoma who had the same
HIV-1 status and whose age was as close as possible to that of
the patient).
The serum samples from these 141 subjects were retested in a
blinded fashion with the immunofluorescence assay, and the in-
tensity of the fluorescent signal was scored again (absent, low,
medium, or high). The results of the repeated test were in com-
plete agreement with those of the first test for the patients with
Kaposi’s sarcoma (40 were positive according to the immunoflu-
orescence assay, and 7 were negative), and in 94 percent agree-
ment for those who did not have Kaposi’s sarcoma (about one
third were positive according to the immunofluorescence assay).
The scores for signal intensity also agreed well: exact agreement
was obtained for 85 percent of those with Kaposi’s sarcoma and
for 90 percent of those without Kaposi’s sarcoma.
To study the relation between the intensity of fluorescence and
the titer of antibodies to HHV-8, the 141 serum samples selected
for retesting were also examined in a blinded fashion at doubling
dilutions, starting at 1:100 for antibodies against HHV-8.
 
30
 
 The
score for the fluorescent-signal intensity was strongly related to
antibody titer — the median titers were 1:200 for low signal in-
tensity, 1:51,200 for medium signal intensity, and 1:204,800 for
high signal intensity (P<0.001) (Fig. 1B).
Testing for HIV-1 was conducted at the Serology Department
of the South African Institute for Medical Research in Johannes-
burg. After presumptive positive results by enzyme-linked immu-
nosorbent assay, the presence of HIV-1 infection was confirmed
in the first study either by Western blot analysis or by three third-
generation tests.
 
12
 
 In the second study, one test was performed
for each patient and those with an equivocal result were consid-
ered to be HIV-1–negative.
 
Statistical Analysis
 
We recruited 3591 patients between 1992 and 1997. Serum
samples from 3344 of them (93 percent) were tested for antibod-
ies to HHV-8, and these results are the basis for the analyses pre-
sented in this report. Since the factors influencing HHV-8 in-
fection in the general population are not known, we initially
examined the relation between antibodies against HHV-8 and
age, sex, education, place of birth, parity, and number of lifetime
sexual partners in the patients without Kaposi’s sarcoma. Odds
ratios were calculated by unconditional logistic regression and,
because information on factors other than age and sex were not
collected in the first study, analyses with respect to the other four
factors were performed for the second study only. The results
were examined at two levels of fluorescence intensity by immu-
nofluorescence assay (i.e., according to whether there was any
positive result, which corresponded to an antibody titer of at least
1:100, and according to whether there were positive results at a
high signal intensity, which corresponded to a median antibody
titer of 1:204,800).
To examine the relation between antibodies against HHV-8
and type of cancer, an unconditional logistic-regression model
was used to calculate the log of the odds of HHV-8 seropositiv-
ity for each type of cancer for which there were 50 or more pa-
tients and for the blood donors, with adjustment for age (<35,
35 to 44, 45 to 54, 55 to 64, or »65 years), sex, years of edu-
cation (unknown, none, one to five, or six or more), and number
of sexual partners (unknown, zero to two, three or four, or five or
more). Since adjustment for years of education and number of
sexual partners had no material effect on the outcome of the
analyses according to cancer type, the results for both studies
were combined, with the patients from the first study assigned
to the unknown categories for years of education and number of
sexual partners. To present these results in a directly interpret-
able form, estimates of the adjusted log (odds) of infection for
each type of cancer were transformed into estimates of standard-
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ized rates of prevalence with corresponding 95 percent confi-
dence intervals. The resulting estimates represent prevalence
rates for each cancer type standardized to a population contain-
ing men and women in equal proportion between the ages of 35
and 44 years, with one to five years of education and three or
four sexual partners.
To study the relation between Kaposi’s sarcoma and fluores-
cent-signal intensity for anti–HHV-8 antibodies separately in
HIV-1–positive and HIV-1–negative patients, floating absolute
risks and their corresponding floated confidence intervals were
calculated,
 
31
 
 with the patients with other cancers as the compar-
ison group. Presentation of the results in this way permitted us
to make valid comparisons between any two groups, regardless of
signal intensity or HIV-1 status, after taking into account the vari-
ation in each floating absolute risk. These risks were calculated
with the use of unconditional logistic-regression models, with ad-
justment for age, sex, and, if known, years of education and num-
ber of sexual partners.
 
Figure 1.
 
 Fluorescent-Signal Intensity and Distribution of Titers of Antibodies against Human Herpes-
virus 8 (HHV-8).
Panel A shows the results of a fluorescence-activated cell-sorter analysis of six patients. The intensity
of the fluorescent signal, as determined by immunofluorescence assay, was low in two patients, me-
dium in two, and high in two. Panel B shows the distribution of titers of anti–HHV-8 antibodies among
those with low-intensity signals, those with medium-intensity signals, and those with high-intensity
signals (those with no signals were excluded). The median titer in each group is indicated by a hori-
zontal line. BCP-1 is a body-cavity–related B-cell lymphoma (primary effusion lymphoma) cell line,
which is positive for HHV-8 and negative for the Epstein–Barr virus.
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RESULTS
 
Antibodies against HHV-8 in Relation to Demographic 
and Behavioral Factors
 
The serum samples of 1196 of the 3293 patients
who did not have Kaposi’s sarcoma were positive for
antibodies against HHV-8 according to the immu-
nofluorescence assay. Of the 1196 positive samples,
58 percent (698 of 1196) had a low fluorescent-sig-
nal intensity, 30 percent (359 of 1196) had a medi-
um intensity, and 12 percent (139 of 1196) had a
high intensity. The seroprevalence of antibodies
against HHV-8 increased steadily with age — from
24 percent for those 15 to 24 years of age to 49 per-
cent for those 65 or more years of age (P<0.001 by
test for trend) (Fig. 2). The corresponding age-spe-
cific seroprevalence rates for patients with a high sig-
nal intensity were 1.0 percent and 7.9 percent, re-
spectively (P for trend, <0.001).
Table 1 shows the age- and sex-adjusted odds ra-
tios for the presence of antibodies against HHV-8
according to sex, years of education, place of birth
(urban or rural area), parity, and number of lifetime
sexual partners. The presence of these antibodies
was not significantly related to sex, place of birth,
or parity. However, the prevalence of seropositivity
decreased with increasing years of education (P for
trend=0.007) and increased with the number of
sexual partners (P for trend=0.05). Broadly similar
relations were seen when the analyses were restrict-
ed to the patients who were seronegative for HIV-1
(Table 1). Adjustment for years of education and
number of sexual partners with respect to the other
factors shown in Table 1 did not alter the results
materially.
 
Antibodies against HHV-8 in Relation to Cancer
 
The presence of antibodies against HHV-8 among
patients with any of 17 types of cancer and among
the black blood donors is shown in Figure 3 at two
levels of fluorescent-signal intensity. Prevalence rates
were standardized according to age, sex, years of ed-
ucation, and number of sexual partners. At each level
of intensity, the standardized prevalence of antibod-
ies against HHV-8 among the patients with Kaposi’s
sarcoma differed significantly from the rates found
for other cancers (for any positive signal, P<0.001;
for a high-intensity signal, P<0.001). The seroprev-
alence rates among those with the other 16 types of
cancer were similar, and there was little evidence of
variation in the rates according to type of cancer (for
any positive signal, P=0.05; for a high-intensity sig-
nal, P=0.3).
The standardized prevalence of antibodies against
HHV-8 among the 51 patients with Kaposi’s sarco-
ma was 83 percent (95 percent confidence interval,
70 to 91 percent) on the basis of the presence of any
 
Figure 2.
 
 Age-Specific Seroprevalence of Antibodies against
Human Herpesvirus 8 (HHV-8) and Human Immunodeficiency
Virus Type 1 (HIV-1) in the Patients without Kaposi’s Sarcoma.
Vertical bars indicate standard errors.
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*Data were not available for all patients for all variables.
†The odds ratios have been adjusted for age and, where appropriate, sex.
CI denotes confidence interval.
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positive signal and 45 percent (95 percent con-
fidence interval, 26 to 66 percent) on the basis of
the presence of a high-intensity signal. The corre-
sponding figures for the patients with all other can-
cers combined were 32 percent (95 percent confi-
dence interval, 28 to 38 percent) and 2.0 percent
(95 percent confidence interval, 1.1 to 3.6 percent),
respectively, which do not differ significantly from
the values for the black blood donors (20 percent
[95 percent confidence interval, 10 to 35 percent]
and 3 percent [95 percent confidence interval, 0.4
to 20 percent]). For the patients with multiple my-
eloma, the corresponding figures were 24 percent
(95 percent confidence interval, 16 to 33 percent)
and 1.5 percent (95 percent confidence interval, 0.5
to 5 percent), and for those with prostate cancer the
figures were 33 percent (95 percent confidence in-
terval, 25 to 43 percent) and 2.4 percent (95 per-
cent confidence interval, 1 to 5 percent). None of
the rates among the patients with myeloma or pros-
tate cancer differed significantly from those among
the patients with cancer other than Kaposi’s sarco-
ma, nor were there any significant trends with in-
creasing signal intensity for the patients with any of
the other cancers.
 
Antibodies against HIV-1 in Relation to Antibodies against 
HHV-8 and the Presence of Kaposi’s Sarcoma
 
The standardized seroprevalence of anti–HIV-1
antibodies was 75 percent among the patients with
Kaposi’s sarcoma and 5 percent among those with
other cancers. As expected, the highest prevalence
rates for anti–HIV-1 antibodies were found in young
adults (Fig. 2), and the prevalence of such antibod-
ies among the patients without Kaposi’s sarcoma in-
creased with the number of sexual partners. The
odds ratio for the presence of HIV-1 antibodies
among the patients with three or four sexual part-
ners, as compared with those with zero to two part-
ners, was 1.3 (95 percent confidence interval, 0.7 to
2.6), and the odds ratio among the patients with five
or more sexual partners, as compared with those
with zero to two partners, was 3.1 (95 percent con-
fidence interval, 1.6 to 6.0).
There was little difference in the standardized
prevalence of antibodies against HHV-8 among the
 
Figure 3.
 
 Standardized Prevalence of Antibodies against Human Herpesvirus 8 (HHV-8) at Two Levels of Fluorescent-Signal Intensity
among 3344 Black South African Patients with Cancer and 85 Black Blood Donors.
The results are given separately for each type or location of cancer that was identified in 50 or more patients. Seroprevalence rates
are standardized according to age, sex, years of education, and number of lifetime sexual partners. Horizontal lines denote 95 per-
cent confidence intervals.
0 10020 40 60 80
Standardized Prevalence (%)
Type or Site of CancerJ
(no. of patients)
Oral cavity (86)J
Esophagus (306)J
Stomach (51)J
Colon or rectum (103)J
Liver (88)J
Lung (117)J
Kaposi’s sarcoma (51)J
Breast (415)J
Cervix (711)J
Ovary (64)J
Prostate (202)J
Other genital (132)J
Hodgkin’s disease (121)J
Non-Hodgkin’s lymphoma (122)J
Multiple myeloma (108)J
Leukemia (280)J
Other cancers (387)J
Blood donors (85)J
J 0 10020 40 60 80
Standardized Prevalence (%)
Presence of Any Positive Signal Presence of High-Intensity Signal
The New England Journal of Medicine 
Downloaded from nejm.org at QUEENSLAND INSTITUTE OF TECHNOLOGY on January 21, 2015. For personal use only. No other uses without permission. 
 Copyright © 1999 Massachusetts Medical Society. All rights reserved. 
 1868
 
·
 
June 17, 1999
The New England Journal  of  Medicine
patients who were seropositive for HIV-1 and those
who were seronegative (30 percent vs. 33 percent).
Only a weak relation was found between the fluores-
cent-signal intensity for anti–HHV-8 antibodies and
HIV-1 infection, with the patients who were sero-
positive for HIV-1 about twice as likely as the sero-
negative patients to have medium-intensity signals
(odds ratio, 2.0; 95 percent confidence interval, 1.3
to 3.2) or high-intensity signals (odds ratio, 2.0; 95
percent confidence interval, 0.9 to 4.4) for anti–
HHV-8 antibodies.
Both among patients who were seronegative for
HIV-1 and those who were seropositive, Kaposi’s
sarcoma was more frequent among those with high-
intensity fluorescent signals for antibodies against
HHV-8 (P<0.001 for trend with increasing signal
intensity) (Fig. 4). However, at each level of HHV-8
signal intensity, Kaposi’s sarcoma was more likely
among the HIV-1–positive patients than among
those who were HIV-1–negative (P<0.001). Since
signal intensity is an indirect measure of antibody ti-
ter, we repeated the analyses using the results from
the 141 patients whose titers of antibody against
HHV-8 had been measured directly. Associations
similar to those shown in Figure 4 were found.
Figure 5 shows the distribution of anti–HHV-8
antibody titers for 47 patients with Kaposi’s sarcoma
and controls matched for age and HIV-1 status.
Eighty-five percent of the serum samples from these
patients had anti–HHV-8 titers »1:100, and 68
percent had titers »1:51,000. The corresponding
figures were 35 percent and 13 percent, respectively,
for the matched controls. Figure 5 also shows that
HIV-1 infection did not have an appreciable effect
on the titer of anti–HHV-8 antibodies.
DISCUSSION
We found that about one third of the serum sam-
ples from the black South African patients with can-
cer whom we studied had antibodies against HHV-8.
In this population, the prevalence of antibodies against
HHV-8 increased with increasing age and a higher
number of sexual partners; it was higher among
those with fewer years of education, but it was not
strongly related to HIV-1 infection. The seropreva-
lence of HHV-8 was highest among the patients with
Kaposi’s sarcoma, as compared with the patients
with any of the other 16 types of cancer studied, in-
cluding multiple myeloma and prostate cancer. Ka-
posi’s sarcoma was more common than other tumors
among patients with high titers of antibody against
HHV-8, and, at a given anti–HHV-8 titer, Kaposi’s
sarcoma was more frequent in HIV-1–positive pa-
tients than in those who were HIV-1–negative.
The black patients with cancers other than Kapo-
si’s sarcoma appeared to be typical of other black
populations in South Africa with respect to HHV-8
infection in that the prevalence of anti–HHV-8 an-
tibodies among them was similar to that among the
black blood donors from the same area (Fig. 3). The
standardized prevalence of antibodies against HHV-8
was substantially greater among black blood donors
than among white blood donors from the same area
(20 percent vs. 5 percent) (unpublished data). With
Figure 4. Risk of Kaposi’s Sarcoma among Patients with Cancer, According to Fluorescent-Signal Intensity and HIV-1
Status.
The floating absolute risks and corresponding 95 percent floated confidence intervals for Kaposi’s sarcoma have been
adjusted for age, sex, years of education, and number of lifetime sexual partners. For the HIV-1–negative patients,
P<0.001 for trend; for the HIV-1–positive patients, P<0.001 for trend. The size of the boxes is inversely related to the
influence of chance. CI denotes confidence interval, and HHV-8 human herpesvirus 8.
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the use of similar assays, less than 5 percent of blood
donors from the United States or the United King-
dom have been shown to have antibodies against
HHV-8.23,25,30
The immunofluorescence assay we used detects an-
tibodies against the latent nuclear antigen of HHV-8
encoded by orf 7327-29; it has been used to study the
seroprevalence of this virus.13,14,21,23,25,26,30 Like other
serologic assays, the immunofluorescence assay is not
sensitive enough to identify every person infected
with HHV-8, but it does detect antibodies against
HHV-8 in over 80 percent of patients with Kaposi’s
sarcoma. Sensitive polymerase-chain-reaction meth-
ods can demonstrate the presence of HHV-8 in the
tumor tissue of virtually all patients with Kaposi’s
sarcoma. On the other hand, the immunofluorescence
assay is highly specific and reveals antibodies against
particular HHV-8 antigens.27-29 An immunofluores-
cence assay against lytically induced HHV-8–posi-
tive cells has been reported to detect infection in a
higher proportion of North American blood donors
than the assay for antibodies against latent HHV-8
antigens used in our study.32 However, that assay is
likely to be less specific than the one we used, be-
cause it detects antibodies against undefined HHV-8
proteins. In blinded comparative studies the immu-
nofluorescence assay we used was shown to be the
most sensitive and specific assay for HHV-8.33 From
an epidemiologic perspective, the immunofluores-
cence assay and the fluorescent-signal-intensity scor-
ing system we used are highly reproducible and cor-
relate well with directly measured titers of antibody
against HHV-8.
Comparatively little is known about factors asso-
ciated with HHV-8 infection in Africa or, indeed,
elsewhere in the world. Studies of homosexual men
in Western countries suggest that the prevalence of
antibodies against HHV-8 increases when sexual
partners are numerous,13,26 findings parallel with our
results. We have shown that among black South Af-
rican patients with cancer other than Kaposi’s sarco-
ma, there is a trend toward increasing prevalence of
antibodies against HHV-8 with increasing numbers
of sexual partners. Our results also suggest that, in
this population, sexual transmission of HHV-8 might
not be as efficient as sexual transmission of HIV-1,
since the odds ratio associated with having had five
or more sexual partners, as compared with zero to
two partners, was only 1.3 (95 percent confidence
interval, 1.0 to 1.7) for antibodies against HHV-8
but 3.1 (95 percent confidence interval, 1.5 to 6.0)
for antibodies against HIV-1.
Furthermore, transmission from mother to child
appears to be common in Johannesburg, with about
one third of the mothers infected with HHV-8
transmitting the virus to their children.14 Therefore,
sexual transmission is clearly not the only mode of
spreading HHV-8 in South Africa, and there may be
other, as yet unknown, routes. The fact that HHV-8
seroprevalence increases with age suggests that the
virus may have been prevalent in this population for
some time — a recently introduced virus that is
transmitted in adults mainly by a sexual route would
be found predominantly among young adults, as is
the case for HIV-1 in this population (Fig. 2) and
throughout Africa. The lower prevalence of anti–
HHV-8 antibodies among whites than among blacks
and the observation that among blacks the preva-
lence declines with increasing education suggest that
factors associated with poverty may contribute to
the transmission of the virus.
Kaposi’s sarcoma was the only cancer among the
17 types we studied that was associated with a high
seroprevalence of antibodies against HHV-8. These
results indicate that HHV-8 has little, if any, specific
association with the other cancers we studied, in-
cluding multiple myeloma and prostate cancer. Al-
though some molecular studies have suggested an
association between HHV-8 and multiple myeloma
or prostate cancer,5,18 various other serologic and mo-
lecular studies have not been able to confirm these
associations.19-21
Kaposi’s sarcoma was especially frequent among
Figure 5. Distribution of Titers of Anti–Human Herpesvirus 8
(HHV-8) Antibodies in 47 Patients with Kaposi’s Sarcoma and
94 Matched Controls. 
For each patient with Kaposi’s sarcoma, two controls without Ka-
posi’s sarcoma were selected, matched for HIV-1 status and age.
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those with high signal intensities in the fluorescent
test and high titers of antibody against HHV-8 (Fig.
4 and 5). This association is similar to the relation
between EBV in African Burkitt’s lymphoma34 and
nasopharyngeal cancer,35 in which high antibody ti-
ters correlate with the risk of disease. Our results were
measured in serum samples collected at the time that
Kaposi’s sarcoma was diagnosed, and no data are
available on how signal intensity or antibody titer
vary over time in the same patient before diagnosis.
It seems unlikely that these associations are a conse-
quence of the disease, since the detection of HHV-8
by the polymerase chain reaction in peripheral-blood
mononuclear cells, which is also an indicator of a
high viral load, has been shown to predict the subse-
quent development of Kaposi’s sarcoma in HIV-1–
positive patients.6,7 In Italy, a study of titers of anti-
bodies against HHV-8 in blood donors found the
highest titers among populations at highest risk for
HIV-1–negative, or classic, Kaposi’s sarcoma.30
HIV-1 infection does not appear to have a sub-
stantial effect on the presence or titer of anti–HHV-8
antibodies (Fig. 5) — further evidence that the
association between the titer of anti–HHV-8 anti-
bodies and Kaposi’s sarcoma is not a consequence of
the disease. Instead, it appears that infection with
HIV-1 has a separate effect with respect to Kaposi’s
sarcoma, which is independent of the anti–HHV-8
antibody titer (Fig. 4). The HHV-8 viral load may
differ between persons infected with HIV-1 and
those who are uninfected who have similar antibody
titers, but relevant data are not yet available. Alter-
natively, HIV-1 infection may affect the development
of Kaposi’s sarcoma in a way that is unrelated to the
HHV-8 viral load, perhaps through HIV-1–related
immune dysregulation or its transactivation (Tat) pro-
tein.36 Currently, however, there is no obvious expla-
nation for our finding of striking differences in the
likelihood of HHV-8–associated Kaposi’s sarcoma
between HIV-1–positive patients and those who were
HIV-1–negative.
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